SGE‐102: A novel therapy for refractory status epilepticus

• Published in: Epilepsia (Copenhagen) Vol. 54; no. s6; pp. 81 - 83
• Main Authors: Reddy, Kiran, Reife, Ross, Cole, Andrew J.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2013
• Subjects: Anticonvulsant; Anticonvulsants - therapeutic use; Clinical trial; Clinical Trials as Topic; GABA Agonists - therapeutic use; gamma-Aminobutyric Acid - metabolism; Humans; Neurosteroid; Phase II; Progesterone - analogs & derivatives; Progesterone - therapeutic use; Randomized; Status Epilepticus - drug therapy; Clinical trial; Anticonvulsant; Neurosteroid; Phase II; Randomized

Summary Refractory status epilepticus (SE) has a mortality rate of up to 35%. Current treatment protocols for the treatment of SE begin with benzodiazepines and then proceed to conventional anticonvulsants. If seizures continue, SE is considered refractory (RSE) and treatment with anesthetic agents...